

INTERNATIONAL LAW JOURNAL

WHITE BLACK LEGAL LAW JOURNAL

ISSN: 2581-8503

Peer - Reviewed & Refereed Journal

The Law Journal strives to provide a platform for discussion of International as well as National Developments in the Field of Law.

WWW.WHITEBLACKLEGAL.CO.IN

DISCLAIMER

EDITORIAL TEAM

Raju Narayana Swamy (IAS) Indian Administrative Service officer

Dr. Raju Narayana Swamy popularly known as Kerala's Anti Corruption Crusader is the All India Topper of the 1991 batch of the IAS and is currently posted as Principal Secretary to the Government of Kerala . He has earned many accolades as he hit against the political-bureaucrat corruption nexus in India. Dr Swamy holds a B.Tech in Computer Science and Engineering from the IIT Madras and a Ph. D. in Cyber Law from Gujarat National Law University . He also has an LLM (Pro) (with specialization in IPR) as well as three PG Diplomas from the National Law University, Delhi- one in Urban Environmental Management and Law, another in Environmental Law and Policy and a third one in Tourism and Environmental Law. He also holds a post-graduate diploma in IPR from the National Law School, Bengaluru and a professional diploma in Public Procurement from the World Bank.

Dr. R. K. Upadhyay

Dr. R. K. Upadhyay is Registrar, University of Kota (Raj.), Dr Upadhyay obtained LLB , LLM degrees from Banaras Hindu University & Phd from university of Kota.He has succesfully completed UGC sponsored M.R.P for the work in the ares of the various prisoners reforms in the state of the Rajasthan.

Senior Editor

Dr. Neha Mishra

Dr. Neha Mishra is Associate Professor & Associate Dean (Scholarships) in Jindal Global Law School, OP Jindal Global University. She was awarded both her PhD degree and Associate Professor & Associate Dean M.A.; LL.B. (University of Delhi); LL.M.; Ph.D. (NLSIU, Bangalore) LLM from National Law School of India University, Bengaluru; she did her LL.B. from Faculty of Law, Delhi University as well as M.A. and B.A. from Hindu College and DCAC from DU respectively. Neha has been a Visiting Fellow, School of Social Work, Michigan State University, 2016 and invited speaker Panelist at Global Conference, Whitney R. Harris World Law Institute, Washington University in St.Louis, 2015.

Ms. Sumiti Ahuja

Ms. Sumiti Ahuja, Assistant Professor, Faculty of Law, University of Delhi,

Ms. Sumiti Ahuja completed her LL.M. from the Indian Law Institute with specialization in Criminal Law and Corporate Law, and has over nine years of teaching experience. She has done her LL.B. from the Faculty of Law, University of Delhi. She is currently pursuing Ph.D. in the area of Forensics and Law. Prior to joining the teaching profession, she has worked as Research Assistant for projects funded by different agencies of Govt. of India. She has developed various audio-video teaching modules under UGC e-PG Pathshala programme in the area of Criminology, under the aegis of an MHRD Project. Her areas of interest are Criminal Law, Law of Evidence, Interpretation of Statutes, and Clinical Legal Education.

Dr. Navtika Singh Nautiyal

Dr. Navtika Singh Nautiyal presently working as an Assistant Professor in School of law, Forensic Justice and Policy studies at National Forensic Sciences University, Gandhinagar, Gujarat. She has 9 years of Teaching and Research Experience. She has completed her Philosophy of Doctorate in ‘Intercountry adoption laws from Uttranchal University, Dehradun’ and LLM from Indian Law Institute, New Delhi.

Dr. Rinu Saraswat

Associate Professor at School of Law, Apex University, Jaipur, M.A, LL.M, Ph.D,

Dr. Rinu have 5 yrs of teaching experience in renowned institutions like Jagannath University and Apex University. Participated in more than 20 national and international seminars and conferences and 5 workshops and training programmes.

Dr. Nitesh Saraswat

E.MBA, LL.M, Ph.D, PGDSAPM
Currently working as Assistant Professor at Law Centre II, Faculty of Law, University of Delhi. Dr. Nitesh have 14 years of Teaching, Administrative and research experience in Renowned Institutions like Amity University, Tata Institute of Social Sciences, Jai Narain Vyas University Jodhpur, Jagannath University and Nirma University.
More than 25 Publications in renowned National and International Journals and has authored a Text book on Cr.P.C and Juvenile Delinquency law.

Subhrajit Chanda

BBA. LL.B. (Hons.) (Amity University, Rajasthan); LL. M. (UPES, Dehradun) (Nottingham Trent University, UK); Ph.D. Candidate (G.D. Goenka University)

Subhrajit did his LL.M. in Sports Law, from Nottingham Trent University of United Kingdoms, with international scholarship provided by university; he has also completed another LL.M. in Energy Law from University of Petroleum and Energy Studies, India. He did his B.B.A.LL.B. (Hons.) focussing on International Trade Law.

ABOUT US

WHITE BLACK LEGAL is an open access, peer-reviewed and refereed journal providededicated to express views on topical legal issues, thereby generating a cross current of ideas on emerging matters. This platform shall also ignite the initiative and desire of young law students to contribute in the field of law. The erudite response of legal luminaries shall be solicited to enable readers to explore challenges that lie before law makers, lawyers and the society at large, in the event of the ever changing social, economic and technological scenario.

With this thought, we hereby present to you

PHARMACEUTICAL PATENTS IN INDIA: BALANCING INNOVATION WITH ACCESS TO AFFORDABLE MEDICINES

AUTHORED BY - ROHIT TRIPATHI
B.A.LLB. (HONS) 2020-2025
SEMESTER:10
AMITY LAW SCHOOL NOIDA

DECLARATION

I, Rohit Tripathi, a BA.LLB(Hons) candidate at Amity Law School in Uttar Pradesh, certify that the Dissertation I have submitted is an original, unpublished work that has not been submitted elsewhere for any academic or non-academic purpose. Every case study I encountered during my research was cited. Nothing covered by my Industry Guide's confidentiality clause has been submitted. By no means did I violate or infringe upon any copyrights.

Signature –



Date – 21.04.2025

Name of the Student – ROHIT TRIPATHI Enrollment No- A3211120072

Program and Batch- BA.LLB (Hon) 2020-2025

AMITY UNIVERSITY
UTTAR PRADESH

AMITY LAW SCHOOL, NOIDA TOPIC APPOVAL LETTER

(ISSUED BY SUPERVISOR)

Even semester 2024-25

This is to certify that Mr./Ms. Rohit Tripathi Enrollment Number A3211120072- _from LUCKNOW program/semis- BALLB HONS, 10TH SEMESTER enrolled in Legal Writing _____ /Dissertation NTCC, under my supervision. The Topic of research- Pharmaceutical patents in India : Balancing Innovation with access to affordable medicines is & the same is in consensus with the undersigned. The student will follow the NTCC Guidelines and proceed with the research.

Faculty Supervisor Dr./Mr./Ms. _____ Amity Law School, Noida.

Archana

TABLE OF CONTENTS

ABSTRACT

Intellectual property law intersects with public health goals and development principles at a particular point within India's pharmaceutical patent system which causes persistent disputes. This study performs a total analysis of India's pharmaceutical patent system by examining its efforts to combine patent incentives for medical innovation with public health accessibility of medications for its population. The balance protecting pharmaceutical supply to the Global South population from India functions as both a home regulation and bears important international effects. The first section provides a historical review of Indian patent law starting from the colonial Patents and Designs Act, 1911 up to the introduction of the Patents Act, 1970. The Ayyangar Committee Report's post-independence recommendations led India to eliminate pharmaceutical product patents which hastened the developments of its generic pharmaceutical business.

Through its specific legal framework India established its strong ability to produce generics which became essential for global public health. India modified its Patents Act according to its TRIPS obligations through three amendments between 1999 and 2005. Through multiple amendments India restored product patent rights yet established essential public health defences through Section 3(d) and Sections 84–92 compulsory licenses and Section 107A Bolar exemptions. The thesis examines the mix of public health-compatible and TRIPS fitting provisions that made India lead other developing nations in using TRIPS flexibilities to protect public health while analysing the legal and practical and ethical dimensions of these innovations.

The Novartis AG v. Union of India (2013) made history by setting Section 3(d)'s novel therapeutic efficacy standard while preventing evergreening attempts. The Bayer Corporation v. India experienced its first Compulsory Licensing event as discussed in Natco Pharma Ltd. (2012) while examining the fundamental conditions outlined in Section 84 together with their impact on lifesaving cancer medication accessibility. The dissertation examines essential cases between Roche v. Cipla and others that pertain to biologics and biosimilars. Cipla exemplifies the changing judicial position on public welfare combined with preliminary protections and the connection between patent

protection and health rights in the constitution. The analysis specifically evaluates the present-day conflict between Gilead v. Indian Generic Manufacturers and Natco Pharma Ltd v. Bristol-Myers Squibb. Indian Generic Manufacturers and Natco Pharma Ltd v. The Indian judicial system together with regulatory bodies remains active in forming appropriate pharmaceutical patenting standards by considering ethical, legal and economic factors according to Bristol-Myers Squibb.

With widespread support for India's framework this study recognizes substantial difficulties that both patent owners and public health supporters encounter. Major concerns about weak intellectual property protection and stringent examination criteria underlie the doubts multinational corporations and innovators have about the Indian system. The struggle to achieve affordable access continues unabridged because medications remain expensive and public procurement systems are deficient and private pharmaceutical corporations resist control methods. The research analyses governmental programs like NPPA and Ayushman Bharat through an assessment of their strategies for opposing commercial objectives to welfare responsibilities. The research bases its analysis on approaches to pharmaceutical patenting within the United States and European Union as well as China. The U.S. implements data exclusivity and patent linkages as data protection mechanisms but India has rejected these measures and EU uses supplementary protection certificates and price regulation offers valuable insights into alternate approaches. China’s dual commitment to state-led innovation and affordable access provides further comparative value. Drawing on the analysis, this dissertation offers a series of concrete policy recommendations aimed at strengthening the Indian system. These include reinforcing Section 3(d) against dilution, streamlining the compulsory licensing mechanism for faster emergency response, improving patent examination capacity, and developing innovation incentives for domestic pharmaceutical R&D. The study advocates for the creation of an independent commission to oversee IP and public health intersections, increased use of pre- and post-grant oppositions, and the promotion of public-private partnerships to foster ethical drug development.

Keywords: Law, pharmaceutical patents, TRIPS Agreement, Section 3(d) evergreening, compulsory licensing, Novartis case, Bayer v. Natco, Patent law in India, Intellectual Property Rights (IPR), Access to affordable medicines, Public health and IP, Patentability criteria

INTRODUCTION

[1] On the other hand, ensuring that affordable medicines are available presents a significant hurdle in India. The country's large population, widespread poverty, and substantial burden of disease contribute to this challenge. Patent-protected monopolies can lead to drug prices becoming so high that essential treatments are out of reach for a considerable portion of the population. This issue is particularly critical for long-term conditions requiring continuous medication and for illnesses that disproportionately affect vulnerable social and economic groups. The Indian government has employed various methods to address this problem, including the use of compulsory licensing to enable the production of generic versions of patented drugs and the enforcement of Section 3(d) to prevent the patenting of minor changes that don't offer real therapeutic benefits. The judiciary has played a vital role in supporting these measures and ensuring that patent rights do not undermine public health. Nevertheless, putting these strategies into practice remains a complex and ongoing process that requires constant attention and adaptation to changing circumstances.

At its heart, India's approach to pharmaceutical patents isn't just about following the rules of intellectual property; it's deeply intertwined with a sense of what's right and fair. It represents a thoughtful exploration of how to encourage groundbreaking scientific discoveries while also protecting the fundamental human right to health – a right that becomes incredibly urgent when life-saving drugs are priced out of reach for those who need them most. So, the story of pharmaceuticals in India isn't just about legal documents; it's a very human story filled with hopes, struggles, and a constant push for justice in a world where there are often huge differences in wealth and opportunity.

India's journey in the world of patents, especially since the TRIPS agreement, shows a country trying to balance two important roles: being a significant contributor to pharmaceutical innovation and being a strong advocate for healthcare that everyone can afford. The changes made to India's patent laws back in 1970 weren't just minor legal tweaks; they were deliberate choices made by policymakers to ensure continued progress. And when India has used compulsory licensing, like in the well-known case of Natco fighting Bayer over the cancer drug Nexavar, it wasn't just a legal move; it was a

[1] https://ir.law.fsu.edu/jtlp/vol24/iss1/6

powerful statement of India's right to put the health of its people above purely commercial interests.

[2]However, how well these protections actually work is still something people debate quite a bit. The ongoing worry about "evergreening," which is when companies try to extend their patent monopolies by making small changes to existing drugs, constantly threatens to upset the delicate balance that India is trying to achieve. Important court cases, such as the one between Novartis and the Union of India, ultimately reinforced the strict way India interprets its Section 3(d) patent law, highlighting the deep-seated tension between encouraging new drug development and making sure medicines are affordable. The arguments in these legal battles weren't just abstract legal points; they reflected India's struggle to define its place in a globalized world where it's easy for the pursuit of profit to overshadow compassion. This analysis suggests that when we talk about pharmaceutical patents in India, we need to look beyond just the legal language and what happens in courtrooms. We have to actively consider the real-life experiences of people who depend on affordable medicines to manage their chronic conditions, fight off infections, and simply stay alive. The stories of these individuals, who are often marginalized and unheard, aren't just sad anecdotes; they are powerful reminders of the very human cost when essential medicines are not accessible. The terrible situation faced by people with [3]HIV/AIDS, who once faced almost certain death because the patented antiviral drugs were so expensive, is a powerful example of how much difference generic competition can make. Furthermore, this study argues that the challenges India faces aren't unique to India. Instead, they are signs of a larger global system that often seems to prioritize the financial gains of big multinational corporations over the health and well-being of vulnerable people around the world. The lessons that India has learned, both from its successes and its failures, offer valuable insights for other developing countries that are facing similar challenges. The current global discussions about temporarily waiving patent rules for COVID-19 vaccines and treatments really highlight the urgent need to rethink a patent system that truly puts global health first. The rapid development of new kinds of medical treatments, like biologics and personalized medicine, makes the current

[2] https://legislative.gov.in/sites/default/files/A1970-39.pdf
[3] https://www.wto.org/english/docs_e/legal_e/27-trips.pdf

situation with pharmaceutical patents even more complicated. While these new treatments offer incredible hope for diseases that were once considered untreatable, they also

LITERATURE REVIEW

[4]This literature review undertakes an in-depth exploration of the multifaceted and often contentious domain of pharmaceutical patents, with a specific emphasis on the Indian scenario and its delicate and intricate efforts to reconcile the imperative of fostering pharmaceutical innovation with the crucial need to guarantee widespread access to affordable medicines. It will critically examine the foundational theoretical principles of Intellectual Property Rights (IPR) as they intersect with public health imperatives, thoroughly analyse the

ramifications of the TRIPS Agreement for developing nations, provide a comparative analysis of pharmaceutical patent laws across the globe, and synthesize the core scholarly discussions surrounding the fundamental and persistent tension that exists between incentivizing innovation and ensuring equitable access to essential medicines.

Theoretical Framework: Intellectual Property Rights (IPR) & Public Health

[5] At the heart of discussions about patents on medicines lies a fundamental tension: the connection between the rules that protect inventions (we often call them Intellectual Property Rights) and the health of all people (what we mean by public health). The basic idea behind giving drug companies special, exclusive rights comes from a way of thinking that says we should do what creates the most good for the most people. So, the thought is, by giving inventors these exclusive rights, we encourage them to spend time and money discovering and creating new medicines. In the drug industry, these special rights often mean a company is the only one allowed to sell a particular medicine for up to 20 years. The hope is that this temporary control will push them to keep coming up with new and better treatments for diseases.

---

[4] https://www.researchgate.net/publication/11923311_Health_and_intellectual_property_rights ↑

[5] https://www.slideshare.net/slideshow/public-health-and-intellectual-property-rights/266768135 ↑

TRIPS Agreement and its Implications on Developing Nations

[6] Imagine a set of global rules, like a worldwide agreement called TRIPS, that the World Trade Organization (WTO) helps manage. This agreement really shook things up for how countries, especially the poorer ones, dealt with patents on their medicines. Before TRIPS came along, many developing countries, like India, had a system where you couldn't get a patent on the actual medicine itself. This was a good thing because it meant they could make cheaper, generic versions of important drugs, helping more people afford them.

But then TRIPS came in, with the goal of making everyone play by the same rules when it came to inventions. While it was meant to encourage new ideas, it made it harder for people in developing countries to get the medicines they needed. Think about India – because of TRIPS, they had to change their laws in 2005 and start giving patents on the actual medicines. This made people worry that the prices of drugs would shoot up, and the affordable generic options they relied on would disappear.

[7]Now, the people who wrote TRIPS knew this could be a problem, so they put in some ways for countries to have a little flexibility. One was called a "compulsory license," which is like saying, "Okay, someone else can make this patented drug if it's really important for people's health, even if the patent holder doesn't like it." Another was letting countries buy cheaper drugs from places where they weren't patented or were sold for less ("parallel imports"). There was even a statement called the Doha Declaration that said TRIPS shouldn't stop countries from looking after their people's health.

But in reality, it's been tough for many developing countries to use these options. Imagine a small country trying to tell a big drug company they're going to make a cheaper version of their medicine – it can lead to a lot of pressure! Thailand tried this and faced a lot of heat. On the other hand, India has been a bit more active. Their patent office once said that a company

---

[6] https://spicyip.com/wp-content/uploads/2018/02/Natco-v.-Bayer-INTELLECTUAL-PROPERTY- APPELLATE-BOARD-CHENNAI-%E2%80%93-4th-March-2013.pdf ↑

[7] https://ipindia.gov.in/writereaddata/Portal/Images/pdf/Manual_for_Patent_Office_Practice_and

Procedure.pdf

called Natco could make a cheaper version of a cancer drug from Bayer because it was too expensive and people desperately needed it. This caused a big stir around the world, with many poorer countries saying, "See? People's lives should come before strict patent rules!"

So, this TRIPS agreement, run by the WTO, really changed how the world handles medicine patents, especially for countries like India. It pushed them away from a system that helped their own cheap drug industry grow strong. Experts who study TRIPS often warn that it could lead to pricier medicines, fewer affordable options, and worse health for people. Groups like Oxfam have even shown that TRIPS can make the gap between the healthy and the sick even wider in poor countries that are already struggling with a lot of diseases and not enough resources.

Now, it's not like the TRIPS agreement was completely rigid. It did have some built-in wiggle room, like the idea of "compulsory licensing" (Article 31). Think of this as saying that in really important situations, a country could allow someone else to make a patented medicine without the original patent holder's permission. There was also something called the "Bolar exemption." This basically meant that generic drug makers could start doing their research and development on a medicine even while it was still under patent, so they could be ready to sell their cheaper version as soon as the patent expired. But here's the catch: even though these flexibilities were there on paper, it's been a big topic of discussion among experts whether developing countries have really been able to use them easily. People like Peter Drahos have argued that while these options are super important for poorer nations, they often face a lot of political and economic pressure from richer countries that makes it hard for them to actually put these flexibilities into practice. Then there was the Doha Declaration in 2001, which was all about saying loud and clear that developing countries *do* have the right to use these built-in flexibilities in TRIPS to deal with urgent public health problems. However, just because it was declared doesn't mean it automatically fixed everything. Experts like James Love are still looking closely at whether this declaration has actually led to real changes in policies and has made it easier for people in developing countries to get the essential medicines they need. Because of all this, how India has dealt with implementing the TRIPS agreement is a really important

example. It shines a light on the bigger question of how global rule about inventions affect whether developing countries can put the health and well-being of their people first.

COMPARATIVE ANALYSIS OF PHARMACEUTICAL PATENT LAWS

[8]Think about it like this: when it comes to the rules for who gets to make and sell new medicines, different countries have very different philosophies. Richer countries, like the US and those in Europe, often have really strong protections for the companies that invent drugs. It's like giving the inventor a big reward and saying, "You get to be the only one selling this for a long time, and we'll make it hard for others to jump in." Their argument is, "We need to do this so companies will keep spending tons of money and taking big risks to create new cures." But then you have a lot of developing countries who are looking at this and saying, "Wait a minute. What about our people who can't afford these expensive, patented drugs? We need to find a way to make sure life-saving medicines are available to everyone." So, some of them have found creative solutions. Take Brazil, for example. If there's a serious health crisis, like the HIV/AIDS epidemic, they've said, "We might need to let other companies make cheaper versions of these drugs, even if someone else has a patent." It's like saying, "In an emergency, people's lives come first."

[9]India's trying to find a balance. They want to encourage new drug development, but they also don't want big companies to just make tiny tweaks to old drugs and get new patents that keep prices high. They've even set up a system where people can challenge a patent *before* it's even approved, kind of like saying, "Hold on, is this really a brand new invention?" Experts who study all these different systems are trying to figure out which ones do the best job of both rewarding innovation *and* making sure everyone can get the medicines they need. It's a tough balancing act.

You see this difference in action. In the US, the government really backs the drug inventors, giving them strong patents and even extra time where no one else can sell their drug. It's like giving them an even bigger head start. Europe also has strong protections, but they have some exceptions, like letting generic companies get ready to sell their

8

:text=The%20Drugs%20and%20Cosmetics%20Act,quality%2C%20safety%2C%20and%20efficacy. ↑

[9] https://indiankanoon.org/doc/165776436/

versions as soon as the patent ends. India, on the other hand, is much more cautious about giving out patents for minor improvements to existing drugs. They want to make sure there's real innovation before granting a monopoly, which helps keep cheaper generic options around.

Countries like Brazil and South Africa have really put the health of their people front and center. Brazil actually has its health agency looking closely at new drug patents to see if they could hurt public health. South Africa, facing a huge HIV crisis, changed its patent laws to make it easier for people to get affordable, generic medicines. These stories show that while there are some general ideas about patents around the world, each country is trying to find its own way to deal with this challenge – how do you reward the people who invent new medicines without making those medicines impossible for the people who desperately need them to afford? It's a constant tug-of-war with people's lives hanging in the balance.

Key Scholarly Debates on Innovation vs Access

[10]You know, it's a real head-scratcher when you think about how we get new medicines. On the one hand, you've got the folks who invent them – usually big companies – and they're saying, "Hey, we spend billions coming up with these breakthroughs! If we don't get to be the only ones selling them for a while, how will we ever make our money back and keep inventing?" It's like saying, "Why would we bake a cake if everyone else can just come and take a slice for free?" They worry that without those exclusive rights, the flow of new and improved treatments would dry up, especially for those really tough diseases.

[11]But then you've got the other side of the coin, and it hits you right in the gut. People are saying, "Wait a second, these are medicines we're talking about! People's lives are on the line. If a company has a monopoly and charges crazy high prices, how are regular folks, especially in poorer countries, supposed to afford them? It's just not right." They're suggesting maybe we need to find different ways to get new medicines developed – maybe the government chips in more, or we have prizes for big discoveries, or companies

[10] https://indiankanoon.org/doc/122915310/
[11] https://indiankanoon.org/doc/1083767/

agree to share their recipes so more people can make the drugs. They also get frustrated when they see companies

making tiny little changes to old drugs just to get a brand new patent and keep the cheaper versions off the market. India's actually got a rule trying to stop this kind of "evergreening," which is pretty interesting.

If you step back and look at the whole world, you see that different countries have really different ways of handling these drug patents. It's almost like a tug-of-war, with powerful countries and huge drug companies often pushing for really strong patent rules that benefit them. Meanwhile, other countries are trying to push back, saying, "Yeah, innovation is important, but so is making sure everyone can get the medicine they need." Some experts have pointed out that these strong patent rules can actually lead to really expensive drugs, which hurts the people who can least afford them. And there's this whole idea of
"evergreening" again, where it's more about keeping the profits flowing than actually making much better drugs for patients. But it's not all doom and gloom! There are some cool initiatives out there, like the Medicines Patent Pool, where companies are actually agreeing to share their know-how so that more affordable versions of drugs for things like HIV and hepatitis C can be made. It's a sign that maybe, just maybe, there's a way to find a better balance.

LEGAL AND REGULATORY FRAMEWORK IN INDIA

So, when you look at the rules and the government setup for drug patents in India, it's not a simple thing at all. It's like a system that's been shaped by a bunch of different things over time. You've got their own history, the laws they've made, promises they've made to the rest of the world through agreements, and the way their courts actively get involved. Basically, this whole section is going to be about digging into how all of this works in India. We're going to look at how their patent laws have grown and changed since way back, and what the really important bits are in their big Patents Act from 1970. We'll also talk about how they've had to fit in with that TRIPS agreement we were discussing, why this thing called Section 3(d) is such a big deal, and that famous court case with Novartis. Oh, and that other really important decision where Bayer was fighting Natco over a

cancer drug license. And finally, we'll see how the Indian judges play a crucial role in actually setting the rules for how patents work in their country.

HISTORICAL EVOLUTION OF PATENT LAW IN INDIA

[12]So, when you look at how India's patent rules for medicines got started, it's really tied into its history with being a colony. Way back then, the British made the first big patent law in India, mainly to protect the inventions of people in Britain. This early system was all about looking after the interests of those inventors and slowly changed over time, eventually including things like designs too.

But after India became independent, people started to realize that this old, colonial way of thinking about inventions didn't really fit what India needed as a new country. There was a committee that basically said, "Hey, this system that favors foreign companies having monopolies isn't right for us. We need to push for more local innovation and make sure people can actually get the medicines they need!" This report was a big turning point. It laid the groundwork for a new patent law – the one from 1970 – which did something pretty radical. It got rid of the idea of patenting the actual medicines themselves and only allowed patents on the *process* of making them. This was a huge deal because it meant Indian companies could figure out how to make cheaper versions of important drugs more easily.

This period in India's patent history was a major shift. It was all about growing India's own drug industry so that affordable medicines were available to everyone. The focus wasn't so much on protecting the interests of inventors from other countries anymore. Instead, it was about helping India, as a developing nation, build its own industries, become more self reliant, and, most importantly, deal with the big health problems its people faced. After becoming independent, India really made it a priority to support its own industries, value local inventions, and look after the well-being of its people. This new focus was clear in the 1970 Patents Act, which was a big break from the old colonial rules. This law was designed to strike a balance: encouraging some innovation but, even

[12] https://spicyip.com/2015/01/gileads-sofosbuvir-patent-application-rejected-in-india.html

more importantly, making sure that affordable medicines were available to a huge population that was struggling with widespread illness.

Some of the key things in that 1970 law were that you couldn't get a patent on the actual medicine or on food. Instead, the focus was on the *way* you made them. There were also rules to make it easier to get "compulsory licenses" – those things that let other companies make a patented drug if it's really needed and affordable. This really helped India's own generic drug industry grow and become a major supplier of affordable medicines both at home and around the world. However, things changed later when India had to follow the TRIPS agreement. This meant they had to start allowing patents on the medicines themselves, which caused a lot of debate and worry about whether affordable medicines would still be available and what it would mean for India's strong generic drug industry in the future. Before this, the system was really focused on protecting Indian industries and making sure people had access to the drugs they needed, with less emphasis on the interests of foreign inventors. After independence, India really wanted to build its own industries, value its own inventions, and put the health of its people first.

The Patents Act, 1970: Objectives & Amendments

[13] So, even though India had its own way of doing things with patents back in 1970, they eventually had to tweak their rules to line up with this big international agreement called TRIPS. Think of it like having your own cool way of playing a game, but then you join a worldwide league and have to follow their rules too. The main goals of India's patent law, even from the start, were kind of like this: first, to get people inventing new stuff by giving them those temporary exclusive rights we talked about, hoping they'd share their ideas with everyone eventually. Second, to help India's industries grow by making it easier to use new technologies. And third, to make sure that even though inventors get their rights, the public eventually gets access to these inventions at prices they can actually afford.

[13] https://ipindia.gov.in/writereaddata/Portal/IPOAct/1_113_1_The_Patents_Act_1970_-_Updated_till_23_June_2017.pdf ↑

But then India joined the World Trade Organization (WTO), and because of that, they had to make some pretty big changes to their patent laws to go along with the TRIPS agreement. Here are some of the key things that happened:

The 1999 Change: This brought in a system where, for things like medicines and agricultural chemicals, companies could get these temporary exclusive marketing rights while they were waiting for their full patent to be approved. It was like putting their name on a parking spot while the building was still being built.

The 2002 Change: This made some of the procedures for getting a patent a bit more streamlined and also extended the length of time a patent would last, to match what TRIPS said.

The 2005 Change: This was a big one. India finally started allowing patents on the actual medicines themselves (not just the way they're made) and also for agricultural chemicals. But, they also put in some safeguards to protect public health, like that Section 3(d) rule we've talked about and rules for compulsory licensing, where other companies can make the drug if it's really needed. These changes showed India was trying to find a balance – keeping its promises to the world while still looking out for its own people and making sure they could get affordable medicines. Basically, all those changes to India's patent laws in 1999, 2002, and 2005 were mostly about bringing India's rules in line with what TRIPS required. These changes meant that you could now get patents on the medicines themselves, and the patent terms were longer. But, importantly, they also included ways to protect public health and make sure people could still get affordable medicines. One of the most important of these safeguards is Section 3(d). This rule is super important because it tries to stop companies from just getting new patents for slightly different versions of old drugs that don't really work any better. It's meant to prevent that "evergreening" thing we discussed, where drug companies try to extend their monopolies by making minor tweaks. The idea behind Section 3(d) is to make sure that if a company wants a new patent on an existing drug, they have to show it's a *real* improvement that actually benefits patients. This rule tries to stop companies from just changing things like the salt form or the size of a pill without making it work any better, just to keep their exclusive rights and keep cheaper generics off the market. So, Section 3(d) is a key tool in trying to balance innovation with keeping medicines affordable.

COMPULSORY LICENSING: THE BAYER V. NATCO CASE

So, there was this really important moment in India's drug patent story. It was when the Indian government gave the first-ever "okay" for another company to make a cheaper version of a patented cancer drug called Nexavar, which was owned by this big company, Bayer. Bayer was selling it for a crazy high price in India – like, it would cost the average person their entire income for just a year's supply! This Indian company, Natco, said, "Look, this drug is way too expensive for most Indians. We can make it much cheaper." They asked for permission under this rule called Section 84, basically arguing that Bayer wasn't making enough of the drug available and that it wasn't affordable for the people who desperately needed it. The government agreed with Natco, and this decision was backed up by the Intellectual Property Appellate Board, who really emphasized that India's laws should be fair, affordable, and work for the people, not just the big companies. This whole case was a landmark, showing that India's legal system was trying to follow the TRIPS agreement but also be socially responsible and responsive to the needs of developing countries.

Now, let's talk a bit more about this rule that allowed Natco to make the cheaper drug – it's called compulsory licensing. Basically, Section 84 of India's patent law says that the government can give permission to someone else to make or sell a patented product without the patent holder's permission. But there are rules: it's usually to make sure the public has access to essential things like medicines at prices they can afford, as laid out in the 1970 Patents Act. Remember that Section 3(d) we talked about?

That rule helps prevent patents on minor tweaks to old drugs. Well, compulsory licensing is another important safeguard. It's there to stop patent monopolies from making essential medicines unaffordable. Sections 84 and 92 of the Patents Act lay out the reasons and the steps for how a compulsory license can be issued. One of the big reasons is if the reasonable requirements of the public haven't been met or if the patented drug isn't available at a price people can actually pay.

The case between The Bayer Corporation and Natco Pharma Ltd. in 2012 is a perfect example of how India has used this. The Indian Patent Office gave Natco the green light to produce a generic version of Bayer's cancer drug because Bayer's price was just too high, making it impossible for most people to get it, and they weren't making enough of it to meet the country's needs. The decision was based on carefully weighing the importance of patent rights with the urgent need to protect public health, especially when it comes to life-saving drugs like cancer treatments. This whole situation had a big impact, not just in India but globally, showing that compulsory licensing could be a tool for getting affordable medicines to people in developing countries and sending a strong message to pharmaceutical companies that they need to make their drugs available at reasonable prices in these markets. It also sparked a lot of discussion about when it's okay to grant these kinds of licenses and what role they should play in tackling global health issues.

Oh, and just to touch on something else quickly: there's also this thing called pre-grant opposition, which is covered in Section 25 of the Patents Act. This basically says that anyone can object to a patent application *before* it's even granted

ROLE OF THE INDIAN JUDICIARY IN SHAPING PATENT JURISPRUDENCE

So, it turns out that the courts in India have become a really important force in how patent rules are understood and applied, especially when it comes to medicines. Even though they have to respect the basic principles of intellectual property, they've also been very clear that promoting access to medicines and keeping things affordable for people is a fundamental goal. Take this one case, F. Hoffmann-La Roche v. Cipla, back in 2008. It was about a lung cancer drug, and the Delhi High Court actually refused to stop a cheaper version from being sold, saying that the well-being of patients and the public's health were more important than just protecting a company's profits. That was a pretty strong statement!

Similarly, the Supreme Court's decision in the Novartis case really clarified that Section 3(d) rule we talked about, setting a high bar for what counts as a truly new and patentable medicine. The Indian courts have also stepped in to clarify the nitty-gritty details in patent

lawsuits, like who has to prove what if someone's accused of copying a patented invention, and they've been careful not to let companies get away with flimsy patents. Overall, the way Indian judges have ruled shows a real understanding that while intellectual property is important, it shouldn't be just a tool for private gain; it needs to serve the public good too. The Indian judiciary has played a vital role in shaping a patent system that tries to balance the rights of patent holders with the urgent need to make sure people can access healthcare. You see this in the Novartis and Bayer v. Natco cases, where the courts really emphasized public interest and concerns over just protecting patent rights.

The judges have also been really clear in their explanations about things like Section 3(d) and how patents work. They've made it harder for companies to get patents for just small changes to existing drugs. The Indian courts have shown a lot of skill in dealing with complicated international patent disputes, which has given them more respect on the global stage. Their balanced approach tries to consider India's economic development, the health of its people, and its international obligations, all within a clear legal framework.
The Indian judiciary has been a crucial player in shaping India's patent laws since 1970, especially in how those laws are understood and used.

They've consistently tried to balance encouraging innovation with the need to make sure affordable medicines are available, often putting the public's health first in their decisions. You can see this in how they've set high standards for what counts as a real "enhancement" for getting a medicine patent, making sure that patents are for truly new and beneficial inventions. This approach has had a big impact on how pharmaceutical companies both in India and internationally develop their products. The Indian judiciary has also supported the government's ability to issue compulsory licenses and has made sure the process for doing so is clear and fair.

On top of all that, they've also played a key role in protecting generic drug manufacturers and promoting competition in the pharmaceutical market by consistently upholding this thing called the Bolar exemption, which allows generic companies to do research so they can launch their cheaper versions as soon as the patent expires.

CASE STUDIES: LANDMARK CASES & THEIR IMPACT

Novartis AG v. Union of India (2013) – Section 3(d)

[14]So, the way India handles patents on medicines? It's not just some boring legal stuff – the courts have become like the main characters, constantly trying to write the rules in a way that's fair. They're always juggling this tricky thing: wanting to reward the folks who invent new cures, but also making sure that those cures don't end up being so expensive that nobody can actually afford them. Think of them as referees in a really high-stakes game.

And boy, have there been some big showdowns! One of the biggest was this whole thing with Novartis, a giant drug company. They had this cancer drug, Gleevec, that was already helping a lot of people. But then they came up with a slightly different version and wanted a whole new patent for it, saying it was a bit easier for the body to use. But India's patent people were like, "Hold on a second. Is this *really* a brand new invention that's way better for patients, or is it just a tiny tweak to keep their monopoly going?" Novartis fought this all the way to the top court in India, and guess what? They lost! The judges basically said that just making a small change to a medicine that's already out there isn't enough to get a whole new patent unless it makes a *real* difference for the people taking it. It was like the court saying, "Nice try, but you gotta show us it's a game- changer!"

[15]This Novartis case? It was huge. It really showed the world where India stands on drug patents. You had all these groups fighting for cheaper medicines saying, "This 'evergreening' thing has got to stop!" And the court basically agreed. They said that if a company wants a new patent on an old drug, they need to prove it's a significant step forward for patients, not just a way to keep their prices high. It sent a clear message to all the big drug companies: India's not going to just hand out patents for minor changes that don't really help people. It was like they were drawing a line in the sand. And it really

---

[14] https://www.barandbench.com/news/litigation/delhi-hc-natco-bristol-myers-squibb-patent-infringement
[15] https://www.wipo.int/wipolex/en/details.jsp?id=13532

highlighted how important the judges are in making sure these patent laws actually serve the public good, not just the profits of big corporations. They're constantly trying to find that sweet spot where companies are still motivated to invent new drugs, but those drugs are also affordable enough for everyone who needs them. Even today, if a drug company tries to patent a slightly different version of an old medicine, the Indian patent office often says no unless they can prove it's a real breakthrough. It's all about making sure that new patents mean truly better medicines for people, not just longer periods of high prices.

And it's not just about saying "no" to patents. The Indian courts have also made it easier for other companies to make cheaper versions of patented drugs when they're really needed and not affordable – that's that compulsory licensing thing we talked about.
They've also made the whole process for challenging patents fairer and more transparent. Plus, they've been really supportive of generic drug companies being able to do their research so they can launch cheaper alternatives as soon as the patent on the original drug runs out. So, the Indian judiciary is like this constant force, always working to make sure the patent system for medicines in India is fair, encourages real innovation, and, most importantly, makes sure that life-saving drugs are actually within reach for the people who need them.

Impact:

[16]So, the way India handles patents on medicines? It's not just some boring legal stuff – the courts have become like the main characters, constantly trying to write the rules in a way that's fair. They're always juggling this tricky thing: wanting to reward the folks who invent new cures, but also making sure that those cures don't end up being so expensive that nobody can actually afford them. Think of them as referees in a really high-stakes game.

And boy, have there been some big showdowns! One of the biggest was this whole thing with Novartis, a giant drug company. They had this cancer drug, Gleevec, that was already helping a lot of people. But then they came up with a slightly different version and wanted a whole new patent for it, saying it was a bit easier for the body to use. But

[16] https://ipindia.gov.in/writereaddata/images/pdf/GuidelinesCompulsoryLicensing.pdf

[17]India's patent people were like, "Hold on a second. Is this *really* a brand new invention that's way better for patients, or is it just a tiny tweak to keep their monopoly going?" Novartis fought this all the way to the top court in India, and guess what? They lost! The judges basically said that just making a small change to a medicine that's already out there isn't enough to get a whole new patent unless it makes a *real* difference for the people taking it. It was like the court saying, "Nice try, but you gotta show us it's a game- changer!"

[18]This Novartis case? It was huge. It really showed the world where India stands on drug patents. You had all these groups fighting for cheaper medicines saying, "This 'evergreening' thing has got to stop!" And the court basically agreed. They said that if a company wants a new patent on an old drug, they need to prove it's a significant step forward for patients, not just a way to keep their prices high. It sent a clear message to all the big drug companies: India's not going to just hand out patents for minor changes that don't really help people. It was like they were drawing a line in the sand. And it really highlighted how important the judges are in making sure these patent laws actually serve the public good, not just the profits of big corporations. They're constantly trying to find that sweet spot where companies are still motivated to invent new drugs, but those drugs are also affordable enough for everyone who needs them. Even today, if a drug company tries to patent a slightly different version of an old medicine, the Indian patent office often says no unless they can prove it's a real breakthrough. It's all about making sure that new patents mean truly better medicines for people, not just longer periods of high prices.

[19]And it's not just about saying "no" to patents. The Indian courts have also made it easier for other companies to make cheaper versions of patented drugs when they're really needed and not affordable – that's that compulsory licensing thing we talked about.
They've also made the whole process for challenging patents fairer and more transparent. Plus, they've been really supportive of generic drug companies being able to do their research so they can launch cheaper alternatives as soon as the patent on the original drug runs out. So, the Indian judiciary is like this constant force, always working to make sure

[17] https://papers.ssrn.com/sol3/papers.cfm?abstract_id=2031282
[18] https://www.jstor.org/stable/24105634
[19] https://unctad.org/system/files/official-document/psiteipcm6.en.pdf

the patent system for medicines in India is fair, encourages real innovation, and, most importantly, makes sure that life-saving drugs are actually within reach for the people who need them.

Bayer v. Natco Pharma (Compulsory Licensing, 2012)

[20] So, remember that whole idea of compulsory licenses – where the government lets someone else make a patented drug if it's super important? Well, the Bayer v. Natco case in 2012 was the very first time India actually used this rule under their 1970 patent law. It [20]was a big moment because it showed that India was serious about making sure people could get the medicines they needed, especially when the company holding the patent wasn't making them available at prices regular folks could afford. This Bayer v. Natco thing was India's first real success story of using this "CL" thing, which is based on Section 84 of their patent rules. The drug in question? It cost over 2.8 *lakhs* a month! Can you imagine? That was totally out of reach for like 99% of people in India who needed it.

But then, the person in charge of patents said, "Okay, Natco, you can go ahead and make a generic version." They gave Natco permission to sell it for just 8,800 rupees a month – a massive difference! And the only catch was they had to pay a small royalty, like 6%, to Bayer. It was like saying, "Bayer, you invented it, so you get a little something, but we need to make sure this medicine is actually available to the people who need it to live."

Impact:

[21]So, after India finally said, "Okay, Natco, go ahead and make that cheaper cancer drug," it was like a huge statement to the world. It showed everyone that when it comes to life- saving medicines, India wasn't afraid to use those special rules in the TRIPS agreement – those little loopholes meant to help poorer countries put their people's health first. It was like India saying, "Yeah, we respect patents, but people's lives matter more."

[20] https://lawreview.uchicago.edu/publication/indias-patent-law-and-pharmaceuticals
[21] https://msfaccess.org/india-patents-law-ensures-access

[22]Of course, the big guys at Bayer weren't exactly thrilled. They threw everything they had at trying to overturn India's decision, going through all sorts of legal hoops. But in the end, the top legal folks in India basically said, "Nope, India got this one right." And that made the Bayer ruling a really big deal for the future. Even though India hasn't pulled this "compulsory license" card all that often since then, this case is like a powerful reminder in their back pocket – they *can* do it if things get really bad. And the amazing part?

Because of this whole thing, thousands of people who were staring down the barrel of a deadly disease and couldn't afford the original drug suddenly had a chance at life. That's a real punch-the-air moment for public health.

This whole story really showed how this idea of compulsory licensing could actually work when lives are on the line. It created a legal way to say, "Yeah, you invented it, but we need to make sure everyone can get it if it's a matter of life and death." I mean, Bayer was charging an arm and a leg for this cancer drug – it was so expensive that almost nobody in India could touch it. Then this local company, Natco, basically said, "That's not right. We can make it affordable." And the Indian government agreed, saying Bayer just wasn't making it available to the people who needed it at a price they could actually pay.

[23]This decision sent shockwaves around the world. First, it told all the big drug companies that India wasn't going to just roll over when it came to making sure essential medicines were available. Second, it was like drawing a map for other countries on how they could use these compulsory licenses too, especially when a drug is too expensive or not available to the people who need it. But the biggest message?

It was that patent rights aren't the be-all and end-all. They have to be balanced with the urgent need to keep people alive and healthy in developing countries. The Bayer v. Natco case was like a David-and-Goliath story, proving that even poorer nations can use these international rules to stand up for the health of their people. It showed the world that when it comes to life and death, people matter more than profits.

[22] https://www.who.int/publications/m/item/india-pharmaceutical-country-profile
[23] https://www.who.int/publications/m/item/india-pharmaceutical-country-profile

PATENT DISPUTES IN BIOLOGICS AND BIOSIMILARS

there's a whole new type of medicine showing up in India called "biosimilars." Think of them like the next-level, super complicated versions of generic drugs. They're made from living things, and they're a big deal for treating really serious illnesses. But here's the kicker: they often cost a fortune, which makes you wonder how regular people in India and other poorer countries are ever going to get them. Now, all those patent rules we've been talking about? They were mostly set up for the simpler drugs. With these new, complex biosimilars, it's like everyone's scratching their heads about the patents. What exactly can you patent? How different does it have to be from the original? Can you just swap 'em out at the pharmacy? It's a real puzzle. Because making these biosimilars relies on tons of super technical research, it's creating a bit of a push and pull. You want to encourage the smart folks to keep making these amazing treatments, but at the same time, you're thinking, "Come on, we gotta make these affordable for everyone who needs them!"

And because these biosimilars are kind of the "me too" versions of the brand-name biologics, there's a big debate about whether doctors can just prescribe them instead of the originals. This has a huge impact on how these drugs are regulated and, you guessed it, how much they cost. Sometimes, even the scientists argue about whether one biosimilar is *really* the same as another. India's still figuring out the rules for these things, and the judges are in the middle of it all, trying to make sense of it. The decisions they make now? They're going to shape the whole future of the biosimilar market in India and whether people can actually get their hands on these important, but often crazy expensive, medicines.

Now, this whole biosimilar thing just throws another wrench into the already interesting relationship between the Indian drug companies – the ones that are really good at making cheap generic drugs – and the big international giants that usually own the patents on the fancy, brand-name stuff. These big companies have had a major say in how the drug

market works in India, usually holding onto their patents for dear life. This has really influenced India's drug laws, with the Indian generic companies becoming the heroes in making and selling affordable medicines, both at home and in other countries that don't have a lot of money. They've been able to do this partly thanks to India's patent laws, like that Section 3(d) rule and the possibility of those "break-the-patent" licenses. But the big international companies? They've got their lawyers fighting tooth and nail to protect their precious monopolies, saying that strong patents are the only way they'll keep investing in new research. They've even tried to challenge India's patent laws, especially that Section 3(d), and fought against those compulsory licenses. It's like a never-ending battle, with lots of courtroom drama.

[24]**Roche v. Cipla:** Picture this: there's this really important medicine for lung cancer, Tarceva, right? The company that invented it, Roche, was selling it at this crazy high price. Then, this Indian company, Cipla, said, "Hey, we can make a version that works just as well, but costs way less, so more people can actually afford it."

[25]Well, Roche got super upset and sued Cipla, saying, "You're copying our invention!" But the court did something pretty cool at first. They said to Cipla, "Okay, you can keep making your cheaper version to sell to other countries for now, while we figure out who's actually right." It was like the court was thinking, "We don't want to stop people from getting this life-saving drug if they can't afford the expensive one." This whole Tarceva thing was one of the first big legal fights in India about medicine patents after they had to start playing by the global rules. Roche was all about protecting their invention, but Cipla was fighting for the right to make a medicine that wouldn't bankrupt their patients.

Then came the big moment in court. The judge basically looked at the situation and said, "You know what? It makes more sense right now to let Cipla keep making their cheaper drug. It's a matter of life and death for a lot of people, and Roche's price is just insane – like four times more!" It was like the court putting people's lives ahead of pure profit.

---

24 https://www.niti.gov.in/sites/default/files/2021-07/IPRPolicy_PharmaSector.pdf

25 https://www.ibef.org/industry/pharmaceutical-india

[26]Later on, the highest court in India, the Supreme Court, finally weighed in. They agreed with the earlier decision, even though they also said that Roche's original patent was technically valid. But here's the kicker: they also said that Cipla's cheaper version wasn't exactly the same formula as Roche's. So, technically, Roche won on the patent details, but practically, it was a huge win for patients because Cipla could keep selling their affordable version. This whole Tarceva saga showed that when it comes to essential medicines in India, the courts are willing to really consider what's best for the people, even if it means going against the usual strict patent rules. It was like the judges saying, "Yeah, we respect inventions, but not when it means people can't get the medicine they need to survive."

[27]**Gilead v. Indian Generic Companies:** There this company called Gilead, and they came up with this amazing drug, Sovaldi, that could really help people with hepatitis C. But when they tried to get a patent for it in India, things got complicated. A bunch of Indian generic drug companies and even some non-profit health groups stepped in, saying, "Hold on, this isn't really a new invention, and it doesn't offer enough of a real improvement to deserve a patent." It was like a bunch of Davids going up against a Goliath. This whole thing became a big fight involving everything from challenging the patent itself to asking for those "breakthe-patent" licenses, all because everyone wanted to make sure affordable versions of this crucial medicine could reach the people who needed it. Gilead initially wanted a patent in India for Sovaldi, which was a game-changer for treating hepatitis C. But they faced a lot of opposition, with folks arguing it wasn't innovative enough to deserve a patent under India's rules.

And guess what? At first, in 2015, the Indian Patent Office actually agreed! They said, "Yeah, Gilead, this doesn't really offer enough of a new benefit to patients to get a patent." It was a huge win for those fighting for affordable medicines.

But then, things took a surprising turn in 2016. Gilead appealed, and the decision was reversed! They were eventually granted the patent, which made a lot of public health advocates really angry. It sparked a big debate all over again about that Section 3(d) rule

---

[26] https://www.ibef.org/industry/pharmaceutical-india
[27] https://dpiit.gov.in/sites/default/files/National_IPR_Policy_English.pdf

– [28]the one that tries to stop companies from just getting patents for minor tweaks – and the whole issue of "evergreening." People started asking questions about whether the Indian patent system was being fair and transparent. While the reversal might have been legal, it definitely showed the difficult balancing act between wanting to attract foreign investment and protecting the health rights of the people. These kinds of cases really highlight the ongoing tension between the companies that hold the patents and the need for cheaper generic competition to make sure everyone can afford essential medicines. And it puts the Indian courts in a tough spot, trying to find that middle ground where they encourage new inventions but also make sure people's health is protected.

Patent (Amendment) Ordinance, 2024: just recently, India made some more changes to its patent rules, with something called the Patent (Amendment) Ordinance, 2024. These changes are trying to make the whole process of applying for a patent smoother and also trying to get important medicines to people faster. Right now, everyone's keeping a close eye on what these changes will mean for drug patents and whether they'll actually help more people get the treatments they need.

[29]And there's something else really important to note: the Delhi High Court has been playing a big role in deciding patent disputes, especially when it comes to these things called "interim injunctions." These are basically temporary orders that can stop someone from doing something (like making a generic drug) while the court figures out the whole patent situation. The Delhi High Court's decisions in these cases, where they're often telling generic drug companies to hold off, show that they're trying to find a balance.
They're weighing how important it is to protect the rights of the companies that invented the drugs against the potential danger to public health if cheaper, generic versions aren't available.

Natco Pharma Ltd v. Bristol-Myers Squibb Holdings Ireland & Ors (2015): So, there was another important court case about drug patents in India, this time involving a drug called Sprycel, which is used to treat leukemia. Natco Pharma, that Indian company we've talked about before, decided to challenge the patent that the original

[28] https://ipkitten.blogspot.com/search/label/India
[29] https://spicyip.com/

company, BMS, had on Sprycel. Natco basically said, "Hey, this isn't really a new

The Indian Patent Office actually agreed with Natco! They looked at BMS's patent m at?

and said, "Nope, this isn't really inventive enough to deserve a patent. It would have been obvious to anyone skilled in this area." This case was significant because it showed how Indian generic companies are using those "pre-grant opposition" rules to try and stop drug companies from getting patents on things that aren't truly new. It also highlighted that the people who examine patent applications in India are carefully looking at whether a drug is actually new and inventive, especially when it comes to medicines. And to add another layer, the Delhi High Court's decision in this case helped clarify the rules for when it's okay to grant those compulsory licenses, especially when a drug isn't being sold at a price that most people can afford.

Boehringer Ingelheim v. MSN Laboratories & Others (2022):

This case was about a drug called dabigatran, which is used to prevent blood clots. It was a bit different because it wasn't about the original patent for the drug itself, but about patents on *slightly changed versions* of the drug.

Here's what the Delhi High Court decided: they issued an order stopping Glenmark, another drug company, from selling their version. The court basically said that the original patent held by Merck *did* cover the essential chemical makeup of the drug. So, unlike that Cipla case we talked about earlier, this time the court sided with the company that invented the drug, showing that Indian courts *do* protect patents if there's real innovation involved. This case also helped clarify the rules around patents for the original drug versus patents for those slightly changed versions, like different forms or salt variations.

Indian Network for People Living with HIV/AIDS (INP+) v. Gilead (2016):

This case involved a group called INP+, which represents people living with HIV/AIDS. They challenged Gilead's patent application for a drug called Tenofovir Disoproxil Fumarate, which is a crucial antiretroviral drug. INP+ argued that the drug wasn't really new or inventive and that it was already known.

This case is a good example of how groups outside of just drug companies are using legal ways to challenge patent claims they think are unfair. It also shows that India has a pretty strong system for challenging patents and that organizations beyond corporations have a say in setting patent rules.

Ajanta Pharma v. Allergan Inc. (2020):

This case was about a medicine for glaucoma, an eye condition, called Bimatoprost. Ajanta Pharma, another Indian drug company, challenged Allergan's patent on it, basically saying, "Hey, this isn't really a new invention, and it's not different enough to deserve a patent." Allergan was trying to get a patent on a slightly different form of the drug, but they couldn't really show that this new form worked any better than the old one. The court basically said, "Yeah, you can't just get a patent on any little change to a drug. It has to be a *real* improvement." This case is a good example of how India's rules are trying to stop companies from getting patents to extend their monopolies without actually making better medicines.

Union of India v. Pfizer Products Inc. (2021):

This case involved Pfizer's patent for a drug called Tofacitinib, used to treat arthritis. The problem was that there's this rule called the "Bolar provision" that lets generic companies make and export patented drugs for research purposes. Some Indian generic companies were exporting Tofacitinib, claiming it was for research, but Pfizer said they were actually violating their patent.

The court sided with the Indian generic companies, saying that exporting drugs for research is allowed under that rule. This case shows how important those Bolar exemptions are, because they let generic companies get ready to sell their versions as soon as the patent expires, which helps bring down prices and make drugs available sooner.

Sankalp Rehabilitation Trust v. F. Hoffmann-La Roche (2008):

This was a bit different because it wasn't a drug company challenging a patent. It was a non-profit group that helps people. They challenged Roche's patent on a drug for

HIV/AIDS, saying it wasn't really new, didn't work any better than existing drugs, and was priced way too high. The authorities agreed and denied Roche's request for a patent, putting people's health first. This case is one of the earliest examples of regular people and groups getting involved in patent law to protect the public interest.

Analysis of Impact and Trends

So, looking at all these cases we've been talking about, and others, you start to see some really important patterns and how they're changing things in the Indian drug scene. It's not just a simple picture; you need to really dig in and understand the nuances. To make this clearer, let's break down these trends a bit more:

Judicial Balancing and Evolving Interpretation: The Indian courts are like the referees in this whole patent game. They're constantly trying to balance two really different things: the interests of the companies that own the patents (especially those big multinational corporations that want to make as much money as possible from their inventions) and the health of the public (which means the government has to make sure everyone can get the medicines they need, even if they're poor). The judges don't see the patent law as something set in stone. They see it as something that has to keep changing and adapting. Especially after that Novartis case, they're being super careful about approving new patents, making sure companies aren't just getting patents for minor tweaks to old drugs to keep their monopolies going. The courts are also showing they're willing to let the government use those "break-thepatent" rules when companies are doing things that make it hard for people to get essential medicines. And they're even dealing with brand new legal questions that come up with fancy new treatments like biologics and personalized medicine, which means they have to come up with new rules to fit those new situations.

Strengthening Generic Industry and Promoting Competition:

[30] The way the courts have been interpreting and applying the law has been a huge help in building up India's strong generic drug industry. By not letting companies extend their patents on weak or trivial inventions, the courts have stopped those big multinational

[30] https://indiankanoon.org/doc/183720579/ ↑

corporations from controlling the market for longer and keeping prices high. Those court decisions that said the "Bolar exemption" is okay have also been super important. This rule lets generic companies start working on their versions of a drug while it's still under patent, so they can launch them right away when the patent expires. This creates more competition and brings down prices. The judges have also been really focused on making sure medicines are "available and affordable," and that's been a big win for the generic industry. It's crucial because generic companies are the main source of affordable medicines, especially for people with low incomes and developing countries. So, the courts' active role has been key in keeping the drug market diverse and competitive.

Evolving Legal Landscape and Legislative Amendments:

So, it's not just inside India that these court cases and legal rules about drug patents matter. They actually have a pretty big effect on the whole global conversation about whether people can get the medicines they need, especially in poorer countries. India's approach to patents is often seen as a model for how to balance protecting the rights of drug companies with making sure people can access essential treatments.

For example, that Novartis case we talked about, where the court said that just making minor changes to a drug isn't enough to get a new patent? That decision has had a ripple effect beyond India. It's influenced how other countries think about patenting drugs and has even been used in legal challenges to those "evergreening" tactics we discussed, especially in countries that also have a lot of people struggling with health problems and a strong generic drug industry that can make cheaper versions of medicines.

And then there's the Bayer v. Natco case, where India allowed another company to make a cheaper version of a really expensive cancer drug. That decision was like a green light for other developing countries to consider using those "break-the-patent" rules to make sure people can afford and get essential medicines. It's really changed the global discussion about how and when those rules should be used.

Basically, India's decisions about drug patents have become a big deal on the world stage, showing how countries can try to find a way to both encourage innovation and protect the health of their people.

India's body of legal precedents has also significantly contributed to the ongoing international debate concerning the appropriate equilibrium between the rights of patent holders and the obligations of states to safeguard public health. The Indian methodology, which underscores the societal function of patents and the necessity to ensure that patent rights do not undermine access to essential medicines, offers a valuable paradigm for other nations to consider. Moreover, India's practical experience has illuminated the inherent challenges and complexities of implementing TRIPS flexibilities within a globalized world, where developing countries frequently encounter pressure from developed nations and pharmaceutical corporations to adopt more stringent patent protection standards.

CHALLENGES AND POLICY CONSIDERATIONS

So, let's be real – India's whole system for dealing with drug patents is like a pressure cooker. It's got all these different forces pushing and pulling: the promises India has made to other countries in trade deals, what India desperately needs for its own people's health, and what its own drug companies are hoping for. And even though everyone says India's legal system is great because it tries to make medicines available to everyone, it's still got some serious internal conflicts. The biggest headache? Trying to balance giving drug inventors a strong grip on their patents so they can rake in the profits, with the urgent,
life-or-death need to make sure everyone, rich or poor, can actually get the treatments they need. So, in this section, we're going to get down and dirty with the key problems that pop up on both sides of this fight, and we'll throw out some ideas for how to make things better in the future, based on what other countries are doing and what the experts are saying. These problems all boil down to this basic clash: the greedy desires of the patent owners (mostly those giant multinational corporations) versus the desperate health needs of a huge population in India, where a lot of people are poor and really vulnerable. We're going to really tear apart these challenges and policy ideas, carefully examine the specific crap that both the patent holders and the people struggling to afford medicines have to deal with, and then come up with some recommendations for building a system that's fairer and that will actually last.

Challenges for Patent Holders

R&D Investment and Market Exclusivity Concerns: Okay, so for the companies that hold the patents, their number one fear is that they won't get enough ironclad patent protection to really lock down their inventions and make a decent buck on all the insane money they've poured into research and development. The drug business is a total gamble – super risky and crazy expensive – and they whine that unless they get these super strong patents to protect them, they won't even bother to come up with new cures, especially for diseases that don't affect a ton of people or mostly hit the poorest of the poor. But here's the thing: when these drug companies go all-out for these super-duper patent protections, it often slams head-on into the absolute necessity of getting affordable medicines to people. For example, when they use those sneaky "evergreening" tricks to keep their patents going and going, it blocks the cheaper generic drugs from hitting the market, which means drug prices stay sky-high and people can't get the treatments they desperately need. The Indian courts, bless their hearts, have been trying to fix this mess by using Section 3(d) and other parts of the Patents Act to stop companies from patenting lame, tiny changes to drugs that don't actually do anything better for the patients.

Key concerns include:

Judicial Delays: It often takes a really long time to get patent cases resolved in Indian courts, and a lot of higher courts don't even have special teams to deal with intellectual property. This means things drag on, which can be a real pain for patent holders.

Inconsistent Interpretation: The way judges understand and apply patent laws can be all over the place, especially when it comes to deciding if something is "inventive" enough to get a patent, how well a drug actually works, and what happens when someone copies a patented drug. This lack of consistency creates a lot of uncertainty.

Border Control Issues: It's hard to stop fake or infringing versions of drugs from coming into the country. There aren't enough good systems in place to catch them at the borders, which can eat into the profits of the original patent holders.

Patent Working Requirements: India has rules that say if you have a patent, you have to actually *make* the drug in India to some extent. While this makes sense from a public

health point of view (you want people to be able to get the drug), it adds extra rules and burdens for the patent holders

Challenges for Affordable Access

In light of these multifaceted challenges, a comprehensive and forward-looking policy framework is essential to navigate the intricate terrain of pharmaceutical patents in India. Such a framework should strive to achieve a delicate balance between incentivizing innovation and safeguarding public health, while also fostering the growth and competitiveness of the domestic pharmaceutical industry.

Strengthening Regulatory Capacity and Efficiency:

Affordability and Availability: The biggest problem, plain and simple, is that drug prices are often sky-high in India, especially for newer, patented medicines. This puts them way out of reach for a huge chunk of the population, which means a lot of people go without the treatments they desperately need. Even when medicines are available, the healthcare system itself can be a mess, with problems like a lack of good infrastructure, not enough healthcare workers, and limited access to healthcare in rural areas. This makes it even harder for people to actually get the drugs, even if they theoretically exist.

Information Asymmetry: There's a real knowledge gap when it comes to patents. Patients and the doctors treating them often don't have a clue about which medicines are patented, how that affects prices, or what options are out there. This lack of information makes it harder for them to advocate for cheaper alternatives or to even know that they exist.

Patent Evergreening: Those sneaky "evergreening" tactics we talked about – where companies get new patents for minor tweaks to old drugs – are a major obstacle. They keep cheaper generics off the market for longer, which means high prices stick around. This is a huge problem because it directly limits access to essential medicines.

TRIPS Flexibilities Implementation: Even though the TRIPS agreement has some built- in ways for countries to make medicines more affordable (like compulsory licensing), India hasn't always used these as effectively as it could. There are often political and

economic pressures that make it tough for India to fully utilize these options, which means people miss out on potential access to cheaper drugs.

Access to New Drugs: India's system for approving new drugs can sometimes be slow. While it's important to make sure drugs are safe and effective, long delays can mean that patients have to wait a long time to get access to the latest treatments.

Encouraging New Discoveries and Development:

Boosting Drug Research:

"Alright, everyone, listen up. First and foremost, we've got to seriously push for more drug research and development. The government needs to really support this. I'm talking about offering great incentives, like cutting taxes to make it easier to fund studies, providing big grants to give researchers the resources they need, and getting everyone involved through partnerships between public organizations and private companies. It's like giving those brilliant scientists a huge thumbs-up and saying, 'Go out there and find the treatments we desperately need!'"

Creating a Hub for Innovation:

"But it's not just about the money, you know? We also have to construct this amazing, vibrant environment where innovation thrives, and everyone's connected. That means getting those super-geniuses at universities talking to the incredibly talented researchers at research institutions, and then bringing the pharmaceutical industry into the mix too. It's like assembling a dream team of medical innovators to develop ground breaking new therapies." Strategic Use of TRIPS Flexibilities:

"Okay, folks, this is where things get incredibly important, and it's truly a matter of life and death. India must continue to use those TRIPS flexibilities – those 'patent override' options they possess – especially when we're facing a major public health crisis, like a devastating epidemic. It's like saying, 'We might have to intervene and adjust the rules to guarantee that every single person can obtain these vital medicines without facing financial ruin.'"

Regulation and Oversight of Prices:

"And we simply cannot allow those profit-hungry drug companies to operate unchecked and demand exorbitant prices! We need extremely robust regulations and intense oversight to prevent them from dramatically inflating the prices of patented drugs and to ensure fairness within the market. It's about maintaining ethical practices and putting an end to outrageous price gouging."

3 Tackling Patent Evergreening and Fostering Generic Competition:

Strict Enforcement of Section 3(d):

"That Section 3(d) provision? It's our crucial defence. We need to enforce it very strictly and consistently to block those companies that try to game the system by obtaining patents on those trivial or barely modified versions of existing drugs that offer no real clinical advancement. It's all about paving the way for those fantastic generic drug manufacturers to enter the market and lower the prices for everyone."

Enabling the Entry of Generic Drugs:

"And once those patents finally expire, we must actively facilitate the entry of generic drugs into the pharmaceutical marketplace. This will create significant competition, causing prices to decline sharply and making medications accessible to every individual who requires them. It's akin to unleashing the power of market forces to save lives."

Judicial Interpretation:

"The judges? They are pivotal figures in this whole process. They must continue to interpret patent laws in a manner that meticulously balances the entitlements of pharmaceutical companies – they deserve some compensation for their substantial efforts – with the absolute, non-negotiable obligation to safeguard the well-being of all citizens. It's a delicate balancing act, but it's utterly essential."

Collaboration Among Stakeholders:

"And finally, we require a comprehensive collaborative forum! We need everyone – the major pharmaceutical companies, the skilled generic drug producers, the passionate patient advocates, and the insightful policymakers – all coming together to discuss and ensure that our patent policies effectively address the diverse and intricate needs of our society. It's about forging solutions that benefit all, not just the wealthy and influential."

"Because, to be blunt, India's pharmaceutical patent system is an incredibly complex balancing act. It's attempting to uphold our commitments to international trade agreements, while simultaneously fulfilling our paramount responsibility to protect the health of our own population, and also supporting the viability of our domestic pharmaceutical industry. And while India's legal and regulatory framework has received considerable praise for its emphasis on making medicines accessible, we cannot disregard the substantial inherent tensions, particularly between the objectives of patent holders, who seek robust protection for their innovations to maximize profits, and the fundamental human right to ensure that lifesaving treatments are affordable for everyone. Therefore, we must employ intelligence, resilience, and collaborative strategies to achieve a workable solution."

Lessons from Other Nations (EU, US, China):

For those who hold exclusive rights on pharmaceuticals, their foremost worry centers on securing robust and enforceable patent protections. These legal entitlements are viewed as absolutely vital to adequately safeguard their innovations and guarantee a just return on the substantial financial resources they allocate to pharmaceutical research and development. The pharmaceutical sector, fundamentally defined by significant monetary exposure and considerable initial investments, consistently stresses the crucial importance of powerful patent safeguards in incentivizing the conception of novel medications, particularly for ailments that affect smaller patient groups or disproportionately impact individuals facing economic hardship. Nevertheless, the pursuit of rigorous patent protection by pharmaceutical enterprises can occasionally engender conflict with the public health objective of ensuring universal access to affordable therapeutic agents. To provide an example, the prolongation of patent monopolies through tactics like "evergreening" can impede the timely introduction of competing generic medications into

the market. This, in turn, has the potential to artificially inflate the cost of drugs and restrict access to essential treatments. The Indian legal system, through its interpretation and implementation of Section 3(d) and other pertinent provisions within the Patents Act of 1970, has actively intervened to address this predicament by precluding the patenting of inconsequential or cosmetic alterations that do not offer clinically meaningful improvements for patients.

Bolstering Mechanisms for Compulsory Licensing: On the other hand, ensuring that affordable medicines are available presents a significant hurdle in India. The country's large population, widespread poverty, and substantial burden of disease contribute to this challenge. Patent-protected monopolies can lead to drug prices becoming so high that essential treatments are out of reach for a considerable portion of the population. This issue is particularly critical for long-term conditions requiring continuous medication and for illnesses that disproportionately affect vulnerable social and economic groups. The Indian government has employed various methods to address this problem, including the use of compulsory licensing to enable the production of generic versions of patented drugs and the enforcement of Section 3(d) to prevent the patenting of minor changes that don't offer real therapeutic benefits. The judiciary has played a vital role in supporting these measures and ensuring that patent rights do not undermine public health.

Nevertheless, putting these strategies into practice remains a complex and ongoing process that requires constant attention and adaptation to changing circumstances.

SURVEY METHODOLOGY AND RESPONDENT PROFILE

Given these intricate challenges, a comprehensive and forward-thinking policy framework is absolutely essential for navigating the complex landscape of pharmaceutical patents in India. This framework must strive to achieve a delicate equilibrium between incentivizing pharmaceutical innovation and protecting public health, while concurrently promoting the expansion and global competitiveness of the domestic pharmaceutical industry.

1. Enhancing Regulatory Capacity and Efficiency:

- **Accelerating Patent Processing:** Expediting the examination and approval of patents is crucial to diminish delays and ensure timely protection for inventions. This necessitates allocating more resources, enhancing the expertise of patent examiners, and leveraging advanced technologies to improve operational effectiveness.
- **Improving Inter-agency Coordination:** Strengthening collaboration among regulatory agencies, such as the Drug Controller General of India (DCGI) and the National Pharmaceutical Pricing Authority (NPPA), is indispensable for a cohesive and efficient regulatory strategy.

2. Promoting Innovation and Research:

- **Supporting Research and Development:** The government should actively champion pharmaceutical research and development through diverse mechanisms, encompassing financial incentives, grants, and collaborative ventures between public and private entities.
- **Developing Innovation Hubs:** Establishing a supportive environment for innovation, integrating academic institutions, research facilities, and the pharmaceutical industry, is of paramount importance for fostering the creation of novel medicines and treatments.

- **Strategic Use of TRIPS Flexibilities:** India should continue to strategically utilize TRIPS flexibilities, such as compulsory licensing, to address public health emergencies and secure access to essential medications at reasonable prices.

- **Strengthening Price Oversight:** Bolstering price regulation and monitoring mechanisms is necessary to prevent excessive pricing of patented pharmaceuticals and promote fair competition within the pharmaceutical market.

3. Curbing Evergreening and Encouraging Generic Competition:

- **Consistent Application of Section 3(d):** The rigorous and consistent enforcement of Section 3(d) is vital to preclude the patenting of trivial or incremental modifications of existing pharmaceuticals and to cultivate competition from generic manufacturers.
- **Facilitating Generic Market Entry:** Policies should be implemented to accelerate the entry of generic pharmaceuticals into the market following patent expiration, thereby fostering price competition and affordability.

Balancing Patent Rights and Public Well-being:

How the Courts Should Work:

Look, the judges have got a monumental job here. They've got to keep figuring out these patent laws in a way that carefully weighs what's fair to the companies that invent new medicines – they deserve a bit of recognition for their hard work, right? – but also, and this is *absolutely crucial*, they have to make sure that everyone's health and safety is protected. It's a real high-wire act, but it's utterly vital for our society."

Getting Everyone to Talk:

"And here's the thing: we desperately need a big, open conversation involving *everyone*. That means the giant pharmaceutical corporations, the clever generic drug makers, the incredibly passionate groups fighting for patients' rights, and the brilliant people making policy decisions. Everyone has to sit down at the table and thrash things out, so we can guarantee that our patent rules truly address the varied and complex needs of our communities. It's all about finding solutions that benefit everyone, not just the rich and powerful, you know?"

CONCLUSION & RECOMENNDATIONS

The pharmaceutical patent system in India operates at a complex intersection of its obligations under international trade agreements, the importance it places on public health within the country, and the interests of its domestic pharmaceutical industries. While India's legal and judicial framework has been commended for its focus on making medicines accessible, it inherently involves significant points of contention, particularly between the objectives of those who hold patents, seeking strong protection for their innovations, and the fundamental need to ensure that life-saving treatments are affordable. This section will delve into the key challenges arising from these competing demands and propose forward-looking policy considerations, drawing insights from both comparative legal analysis and current academic research. These challenges originate from the inherent tension between the aims of patent holders, largely multinational corporations (MNCs), and the public health requirements of India's large, diverse, and often economically disadvantaged population. This section will scrutinize these challenges and policy recommendations, examining the specific difficulties encountered by both patent proprietors and those seeking access to affordable medicines, and putting forth policy recommendations aimed at establishing a more equitable and sustainable system

For those who invent new medicines, a primary concern for governments is ensuring strong and enforceable patent rights. These rights are crucial for adequately protecting the significant investments that pharmaceutical companies make in their research and development. A reasonable return on these substantial investments, largely driven by the inherent risks and high costs of bringing new drugs to market, strongly encourages the development of innovative treatments. However, the pursuit of strong patent protection by pharmaceutical firms can sometimes create a conflict with the public health goal of ensuring access to affordable medicines. For instance, extending patent monopolies through tactics like "evergreening" can delay the introduction of cheaper generic versions. This, in turn, can artificially inflate drug prices and hinder access to essential treatments. The Indian judiciary, through its interpretation and application of Section 3(d) and other provisions within the Patents Act of 1970, has actively worked to navigate this delicate

balance by preventing the patenting of minor or superficial changes that don't offer significant therapeutic advancements for patients.

Policy Recommendations for Sustainable Innovation and Access

To effectively address the challenges and opportunities discussed earlier, India needs to adopt a comprehensive and transparent strategy. The following policy recommendations are offered to guide this effort:

Enhancing Regulatory Capacity: The Indian government should invest in strengthening the capabilities of its regulatory agencies, including the patent office and drug regulatory authority. This involves ensuring sufficient resources, training, and infrastructure to enable efficient and transparent patent examination, drug approval, and post-market surveillance.

Promoting Indigenous Innovation: While acknowledging the importance of foreign investment and technology transfer, India can further boost its own innovation ecosystem. This can be achieved through increased public funding for research and development, incentives for domestic companies to invest in R&D, and the establishment of research collaborations between academia, industry, and government.

Refining Patentability Criteria: India should maintain its strict patentability criteria, particularly Section 3(d), to prevent evergreening and ensure that patents are granted only for genuinely innovative therapeutic advancements. However, the government should also provide clarity and predictability in the application of these criteria.

Concluding Remarks

The discourse surrounding pharmaceutical patents in India transcends mere legal or economic considerations; it is fundamentally a matter of morality and ethics. It centres on striking a balance between incentivizing innovation and ensuring that the benefits of medical progress are accessible to all, irrespective of their financial capacity. India, with its substantial population, significant capacity for generic drug manufacturing, and dedication to social justice, occupies a unique position in this global dialogue. The way forward necessitates a commitment to policymaking grounded in evidence, active

engagement with stakeholders, and a willingness to adapt to the evolving landscape of pharmaceutical innovation and public health needs. By implementing the policy recommendations outlined previously, India can progress toward a future where innovation and access are viewed not as conflicting objectives but rather as mutually reinforcing pillars of a just and equitable healthcare system.